

Press release

Vexim: Amendment of the financial agenda for 2017

Toulouse (France), January 30th, 2017 (8:30AM CET) –VEXIM (FR0011072602 – ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, will announce its 2016 Full-Year Results on Wednesday, 22 March, 2017 – before the market opening.

The other dates announced on the original schedule remain unchanged:

Announcement	Date*
2016 Full-Year Sales	Tuesday January 17 th , 2017
2016 Full-Year Results	Wednesday March 22 nd , 2017
1 st quarter 2017 Sales	Wednesday April 19 th , 2017
Annual General Meeting	Wednesday May 24 th , 2017
2017 Half-Year Sales	Tuesday July 11 th , 2017
2017 Half-Year Results	Thursday September 14 th , 2017
3 rd quarter 2017 Sales	Thursday October 12 th , 2017
<i>Financial year ended December 31</i>	

* Subject to modification. Press releases are distributed either before the financial markets opening, or after the closure

Financial reporting schedule:
2016 Full-Year Results: March 22nd, 2017¹

¹ Indicative date, subject to changes.

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholder, Truffle Capital² and from BPI public subsidies, VEXIM has designed and developed the SpineJack[®], a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The company also developed the Masterflow[™], an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure. The company counts 66 employees, including its own sales teams in Europe and a network of international distributors.

VEXIM has been listed on Alternext Paris since May 2012. For further information, please visit www.vexim.com

SpineJack[®] ³, a revolutionary implant for treating Vertebral Fractures

The revolutionary aspect of the SpineJack[®] lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack[®] range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral fractures and all patient morphologies. SpineJack[®] technology benefits from the support of international scientific experts in the field of spinal surgery and worldwide patent protection through to 2029.

Masterflow[™] ², a high-performance orthopedic cement delivery system

The Masterflow[™] is an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure for treating vertebral compression fractures. The device provides a better control of the injection of biomaterials into the spine. A complement of the SpineJack[®], the Masterflow[™] stands out for being both easy to use and precise, particularly in its ability to stop the cement delivery instantly without inertia. The Masterflow[™] contributes to reducing pain in patients. Its first sales were recorded in the U.S. in February 2015, and the system has also received the CE marking in February 2015, a mandatory conformity mark for products marketed in Europe.

CONTACTS

VEXIM


Vincent Gardès, CEO
José Da Gloria, Chief Financial Officer
investisseur@vexim.com
Tél. : +33 5 61 48 48 38

PRESS

ALIZE RP
Caroline Carmagnol / Wendy Rigal
vexim@alizerp.com
Tél. : +33 1 44 54 36 66
Tél. : +33 6 48 82 18 94



Name : VEXIM
ISIN code : FR0011072602
Ticker : ALVXM



² Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

³ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.